162 related articles for article (PubMed ID: 24588075)
41. [The liver and methotrexate].
Laharie D; Terrebonne E; Vergniol J; Chanteloup E; Chabrun E; Couzigou P; de Lédinghen V
Gastroenterol Clin Biol; 2008 Feb; 32(2):134-42. PubMed ID: 18494155
[TBL] [Abstract][Full Text] [Related]
42. Serum aminoterminal propeptide of type III procollagen. A non-invasive test for liver fibrogenesis in methotrexate-treated psoriatics.
Zachariae H; Søgaard H; Heickendorff L
Acta Derm Venereol; 1989; 69(3):241-4. PubMed ID: 2566230
[TBL] [Abstract][Full Text] [Related]
43. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic.
Barker J; Horn EJ; Lebwohl M; Warren RB; Nast A; Rosenberg W; Smith C;
J Eur Acad Dermatol Venereol; 2011 Jul; 25(7):758-64. PubMed ID: 21198946
[TBL] [Abstract][Full Text] [Related]
44. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study).
Degos F; Perez P; Roche B; Mahmoudi A; Asselineau J; Voitot H; Bedossa P;
J Hepatol; 2010 Dec; 53(6):1013-21. PubMed ID: 20850886
[TBL] [Abstract][Full Text] [Related]
45. Enhanced liver fibrosis test in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional comparison with procollagen-3 N-terminal peptide (P3NP).
van der Voort EAM; Wakkee M; Veldt-Kok P; Darwish Murad S; Nijsten T
Br J Dermatol; 2017 Jun; 176(6):1599-1606. PubMed ID: 27925155
[TBL] [Abstract][Full Text] [Related]
46. Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis.
Kanzler MH; Gorsulowsky D
J Am Acad Dermatol; 1992 Mar; 26(3 Pt 2):509. PubMed ID: 1564165
[No Abstract] [Full Text] [Related]
47. Transient Elastography May Improve Detection of Liver Fibrosis in Psoriasis Patients Treated with Methotrexate.
Talme T; Nikamo P; Rosenberg P; Ståhle M
Acta Derm Venereol; 2017 Aug; 97(8):952-954. PubMed ID: 28422266
[No Abstract] [Full Text] [Related]
48. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.
Laharie D; Seneschal J; Schaeverbeke T; Doutre MS; Longy-Boursier M; Pellegrin JL; Chabrun E; Villars S; Zerbib F; de Lédinghen V
J Hepatol; 2010 Dec; 53(6):1035-40. PubMed ID: 20801541
[TBL] [Abstract][Full Text] [Related]
49. Reliability of the Roenigk classification of liver damage after methotrexate treatment for psoriasis: a clinicopathologic study of 160 liver biopsy specimens.
Berends MA; van Oijen MG; Snoek J; van de Kerkhof PC; Drenth JP; Han van Krieken J; de Jong EM
Arch Dermatol; 2007 Dec; 143(12):1515-9. PubMed ID: 18087000
[TBL] [Abstract][Full Text] [Related]
50. Dynamic hepatic scintigraphy in the screening of psoriatic patients for methotrexate-induced hepatotoxicity.
McHenry PM; Bingham EA; Callender ME; Delvin PB; O'Hara MD; Ferguson WR; Laird JD; Burrows D
Br J Dermatol; 1992 Aug; 127(2):122-5. PubMed ID: 1390139
[TBL] [Abstract][Full Text] [Related]
51. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment.
Rosenberg P; Urwitz H; Johannesson A; Ros AM; Lindholm J; Kinnman N; Hultcrantz R
J Hepatol; 2007 Jun; 46(6):1111-8. PubMed ID: 17399848
[TBL] [Abstract][Full Text] [Related]
52. The value of a baseline liver biopsy prior to methotrexate treatment.
Dolan OM; Burrows D; Irvine A; Walsh M
Br J Dermatol; 1994 Dec; 131(6):891-4. PubMed ID: 7857846
[TBL] [Abstract][Full Text] [Related]
53. Comparison of diagnostic accuracy of magnetic resonance elastography and Fibroscan for detecting liver fibrosis in chronic hepatitis B patients: A systematic review and meta-analysis.
Xiao H; Shi M; Xie Y; Chi X
PLoS One; 2017; 12(11):e0186660. PubMed ID: 29107943
[TBL] [Abstract][Full Text] [Related]
54. Ultrasound Shear Wave Elastography for Liver Disease. A Critical Appraisal of the Many Actors on the Stage.
Piscaglia F; Salvatore V; Mulazzani L; Cantisani V; Schiavone C
Ultraschall Med; 2016 Feb; 37(1):1-5. PubMed ID: 26871407
[TBL] [Abstract][Full Text] [Related]
55. Diagnosing liver fibrosis: a narrative review of current literature for dermatologists.
Potts JR; Maybury CM; Salam A; Barker JN; Agarwal K; Smith CH
Br J Dermatol; 2017 Sep; 177(3):637-644. PubMed ID: 27995624
[TBL] [Abstract][Full Text] [Related]
56. Liver fibrosis quantified by image analysis in methotrexate-treated patients with psoriasis.
Nohlgård C; Rubio CA; Kock Y; Hammar H
J Am Acad Dermatol; 1993 Jan; 28(1):40-5. PubMed ID: 7678843
[TBL] [Abstract][Full Text] [Related]
57. Psoriasis, transient elastography and methotrexate: monitoring at a tertiary hospital.
Koch K
Australas J Dermatol; 2021 Feb; 62(1):69-70. PubMed ID: 32700316
[No Abstract] [Full Text] [Related]
58. Methotrexate hepatotoxicity and concentrations of methotrexate and folate in erythrocytes--relation to liver fibrosis and cirrhosis.
Zachariae H; Schrøder H; Foged E; Søgaard H
Acta Derm Venereol; 1987; 67(4):336-40. PubMed ID: 2445154
[TBL] [Abstract][Full Text] [Related]
59. The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate-induced hepatic damage in psoriasis patients.
vanDooren-Greebe RJ; Kuijpers AL; Buijs WC; Kniest PH; Corstens FH; Nagengast FM; de Boo T; Willems JL; Duller P; van de Kerkhof PC
Br J Dermatol; 1996 Mar; 134(3):481-7. PubMed ID: 8731673
[TBL] [Abstract][Full Text] [Related]
60. [Current topics in psoriasis].
Boulinguez S
Ann Dermatol Venereol; 2011 Jun; 138(6 Suppl 1):H1-5. PubMed ID: 21703467
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
